156 related articles for article (PubMed ID: 24423810)
1. Association of physician specialty and medical therapy for benign prostatic hyperplasia.
Han LC; Kim SP; Gross CP; Ross JS; Van Houten HK; Smaldone MC; Krambeck AE; Shah ND
Med Care; 2014 Feb; 52(2):128-36. PubMed ID: 24423810
[TBL] [Abstract][Full Text] [Related]
2. Differences in initial benign prostatic hyperplasia management between primary care physicians and urologists.
Hollingsworth JM; Hollenbeck BK; Daignault S; Kim SP; Wei JT
J Urol; 2009 Nov; 182(5):2410-4. PubMed ID: 19765742
[TBL] [Abstract][Full Text] [Related]
3. Prescriber monitoring for benign prostatic hyperplasia within a family medicine clinic: a comparison of medication classes.
Sherman JJ; Welch RW; Hill TM; McEwen C
J Pharm Pract; 2012 Apr; 25(2):164-8. PubMed ID: 22215645
[TBL] [Abstract][Full Text] [Related]
4. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.
Duan Y; Grady JJ; Albertsen PC; Helen Wu Z
Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):340-348. PubMed ID: 29316005
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Combination Therapy Versus Monotherapy in Benign Prostatic Hyperplasia: A Colombian Experience.
Guevara-Cuellar CA; Parody-Rúa E; Garcia-Perdomo HA; Arenas-Duque A
Value Health Reg Issues; 2018 Dec; 17():174-182. PubMed ID: 30415110
[TBL] [Abstract][Full Text] [Related]
6. Management of lower urinary tract symptoms related to benign prostatic hyperplasia in real-life practice in france: a comprehensive population study.
Lukacs B; Cornu JN; Aout M; Tessier N; Hodée C; Haab F; Cussenot O; Merlière Y; Moysan V; Vicaut E
Eur Urol; 2013 Sep; 64(3):493-501. PubMed ID: 23465519
[TBL] [Abstract][Full Text] [Related]
7. α-Blockers for benign prostatic hyperplasia: the new era.
Lepor H; Kazzazi A; Djavan B
Curr Opin Urol; 2012 Jan; 22(1):7-15. PubMed ID: 22080875
[TBL] [Abstract][Full Text] [Related]
8. Patient characteristics and treatment patterns for patients with benign prostatic hyperplasia, erectile dysfunction or co-occurring benign prostatic hyperplasia and erectile dysfunction in general practices in the UK: a retrospective observational study.
Ilo D; Raluy-Callado M; Graham-Clarke P; Sadasivan R; Birt J; Donaldson R; Zhu E; Kirby MG; Neasham D
Int J Clin Pract; 2015 Aug; 69(8):853-62. PubMed ID: 26011100
[TBL] [Abstract][Full Text] [Related]
9. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
10. Benign prostatic hyperplasia evaluation, treatment and association with sexual dysfunction: practice patterns according to physician specialty.
Seftel AD; Rosen RC; Rosenberg MT; Sadovsky R
Int J Clin Pract; 2008 Apr; 62(4):614-22. PubMed ID: 18266709
[TBL] [Abstract][Full Text] [Related]
11. The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.
Fonseca J; Martins da Silva C
Clin Drug Investig; 2015 Feb; 35 Suppl 1():7-18. PubMed ID: 25708606
[TBL] [Abstract][Full Text] [Related]
12. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications.
Seftel A; Rosen R; Kuritzky L
Int J Impot Res; 2007; 19(4):386-92. PubMed ID: 17377613
[TBL] [Abstract][Full Text] [Related]
13. Risk of Incident Antidepressant-Treated Depression Associated with Use of 5α-Reductase Inhibitors Compared with Use of α-Blockers in Men with Benign Prostatic Hyperplasia: A Population-Based Study Using the Clinical Practice Research Datalink.
Hagberg KW; Divan HA; Nickel JC; Jick SS
Pharmacotherapy; 2017 May; 37(5):517-527. PubMed ID: 28295443
[TBL] [Abstract][Full Text] [Related]
14. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
Morlock R; Goodwin B; Gomez Rey G; Eaddy M
Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
[TBL] [Abstract][Full Text] [Related]
15. Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery.
Souverein PC; Erkens JA; de la Rosette JJ; Leufkens HG; Herings RM
Eur Urol; 2003 May; 43(5):528-34. PubMed ID: 12705998
[TBL] [Abstract][Full Text] [Related]
16. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.
Montorsi F; Henkel T; Geboers A; Mirone V; Arrosagaray P; Morrill B; Black L
Int J Clin Pract; 2010 Jul; 64(8):1042-51. PubMed ID: 20487046
[TBL] [Abstract][Full Text] [Related]
17. Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry.
Wei JT; Miner MM; Steers WD; Rosen RC; Seftel AD; Pasta DJ; Carman WJ; Roehrborn CG;
J Urol; 2011 Sep; 186(3):971-6. PubMed ID: 21791352
[TBL] [Abstract][Full Text] [Related]
18. Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia.
Zabkowski T; Saracyn M
J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30552307
[TBL] [Abstract][Full Text] [Related]
19. The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia.
Agha AH; Roy JB; Culkin DJ; Lyon K
Adv Ther; 1995; 12(6):361-6. PubMed ID: 10163332
[TBL] [Abstract][Full Text] [Related]
20. Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.
Elterman DS; Lawrentschuk N; Guns E; Hersey K; Adomat H; Wood CA; Fleshner N
J Urol; 2010 May; 183(5):2085-9. PubMed ID: 20303529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
